Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
Published Online: 2021-04-?
Journal: The Lancet Haematology•Publisher: Elsevier BV
Authors: Alexander Zweibach•Anthony R Mato•Danielle M Brander•Frederick Lansigan•Hari P Miskin•Ian W Flinn•Jason C Chandler•Jeff P Sharman•John M Burke•Kathryn S Kolibaba•Marshall T Schreeder•Michael S Weiss•Mikhail Shtivelband•Nilanjan Ghosh•Patrick M Travis•Peter Sportelli•Scott D Lunin•Stephen J Schuster•Suman Kambhampati
